<DOC>
	<DOCNO>NCT02677259</DOCNO>
	<brief_summary>Optimizing vitro fertilization ( IVF ) success important ever , light new public funding IVF Ontario , Canada . In patient undergo IVF use gonadotropin-releasing hormone ( GnRH ) analogue , luteal phase appear compromise , may result controlled-ovarian hyperstimulation , significant fluctuation hormone level , impact oocyte retrieval process , direct compromise corpus luteum . Progesterone support definitely necessary luteal phase facilitate implantation whether estrogen supplementation also need remains unclear . The present study aim determine whether estradiol support luteal phase improve clinical pregnancy rate patient undergo IVF .</brief_summary>
	<brief_title>Luteal Phase Estradiol Support In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles</brief_title>
	<detailed_description>Background : It well establish luteal phase compromise IVF cycle use GnRH analogue . Use GnRH agonists antagonist result decrease production estrogen progesterone , decrease luteal phase length , impair endogenous gonadotropin secretion cause persistent pituitary suppression . While benefit progesterone support luteal phase IVF cycle well establish , role estrogen support luteal phase less clear . The corpus luteum produce progesterone estradiol support endometrium implantation . Estrogen produce luteal phase modulate concentration progesterone receptor within secretory endometrium effort maintain sufficient receptor concentration progesterone stimulation . Stewart et al . highlight importance luteal phase serum estradiol concentration observe significant difference midluteal serum estradiol concentration conception non-conception cycle . This observation appear hold true patient undergo IVF well . Shahara et al . demonstrate , absolute estradiol level , also magnitude estradiol decline ( measure ratio peak estradiol time hCG administration midluteal estradiol ) predictive IVF success . These study support idea luteal phase estradiol supplementation may important implantation IVF success . Studies investigate effect luteal phase estradiol supplementation produce conflicting result . In small randomized , control trial ( RCT ) Farhi et al. , IVF patient receive oral estradiol vaginal progesterone luteal phase support achieve high clinical pregnancy implantation rate patient receive vaginal progesterone alone . Lukaszuk et al . confirm finding find significant benefit occur high dose estradiol administer ( 6mg ) . Elgindy et al . observed correlation mid-luteal serum estradiol concentration clinical pregnancy rate patient receive 6mg oral estradiol15 . Similar benefit luteal phase estradiol support demonstrate vaginal transdermal formulation . Conversely , multiple old study fail demonstrate benefit luteal phase estradiol support IVF cycle . Lin et al. , RCT 402 patient undergoing IVF , find benefit luteal phase oral estradiol . This finding support study investigate vaginal transdermal formulation luteal phase estradiol support . A recent meta-analysis also demonstrate statistically significant benefit luteal phase estradiol administration IVF outcomes , though common odds ratio 1.18 ( 95 % CI : 0.98 , 1.41 ) p value 0.07 . Significant heterogeneity observe included study author admit large-scale RCTs need appropriately address question . Since trial do , major shift away long GnRH agonist stimulation short protocol GnRH antagonist use . All three study luteal phase estradiol support focus IVF cycle use old GnRH agonist protocol give frequency application . The study use GnRH antagonist protocol show benefit luteal phase estradiol support study small scale ( total n=426 ) fail report important outcome clinical pregnancy rate . Both GnRH agonists antagonist suppress pituitary gonadotropin production lead luteal phase deficiency . GnRH antagonists appear promote premature luteolysis cause reduction luteal phase length ultimately decreased pregnancy rate . Given frequency protocol use IVF , large-scale study greatly need address role estradiol luteal phase supplementation . It well establish luteal phase IVF cycle use GnRH analogue compromise form luteal phase support require . Compelling evidence exists support use luteal phase progesterone role estradiol remain controversial . Most existing study small size lack sufficient power . Few study exist determine role estrogen supplementation GnRH antagonist IVF cycle . This well-powered RCT address important clinical question . Methods : Design : This single center RCT , conduct ONE Fertility Burlington . Inclusion criterion : Indications IVF/ICSI include male factor , diminish ovarian reserve , tubal factor , ovulatory dysfunction unexplained infertility . Female age 42 year less . IVF protocol : A short , GnRH antagonist protocol use patient . Starting cycle day 3 , ovarian stimulation perform use combination recombinant follicle-stimulating hormone ( FSH ) ( Puregon , Ferring , ; Gonal-F , EMD Serono ) , medication mimic luteinizing hormone ( LH ) activity , i.e recombinant human choriogonadotropin ( hCG , Ferring ) and/or medication contain FSH LH ( Menopur , Ferring ) . Medications dose accord patient 's diagnosis ovarian reserve measurement . Follicular development monitor serial transvaginal ultrasound , serum estradiol , progesterone LH concentration . A GnRH antagonist ( Orgalutran , EMD Serono ) commence pituitary suppression cycle day 6 9 . Oocyte retrieval perform 36 hour administration choriogonadotropin alpha ( Ovidrel , EMD Serono ) , GnRH agonist ( Decapeptyl , Ferring ) , complete oocyte maturation sufficient cohort mature follicle identify . A maximum 2 embryo transfer either day 3 day 5 follow oocyte retrieval . Serum beta hCG measurement perform 17 day oocyte retrieval , positive , clinical pregnancy confirm every 2 week commence 6 week gestation 12 week gestation . Recruitment Randomization : Recruitment occur inform consent obtain time treatment consent . Participants randomize time recruitment way number , seal envelope receive either 17-beta estradiol 3 mg PO/PV BID plus micronized progesterone 200 mg PV TID ( treatment group ) micronized progesterone alone ( control group ) luteal support commence day oocyte retrieval . 17-beta estradiol continued time pregnancy test , β-hCG positive , 6 week gestation ( 4 week total ) . Progesterone continue time pregnancy test , β-hCG positive , 10 week gestation ( 8 week total ) . There blind group allocation placebo . Subjects assign unique subject number prior data analysis order avoid use identify information . Data collect use standardized patient data form secure computerized database . Outcomes : The primary outcome clinical pregnancy , define presence fetal heart activity ultrasound beyond 6 week gestation . Secondary outcome include ongoing pregnancy rate ( number clinical pregnancy ultrasound continue beyond 12 week gestation/number clinical pregnancy ) , implantation rate ( number clinical pregnancies/number embryo transfer ) , luteal phase serum estradiol progesterone concentration ( perform oocyte retrieval , 10 day retrieval , time serum pregnancy test , i.e . 17 day retrieval ) , miscarriage rate ( number pregnancy loss 20 weeks/number clinical pregnancy ) ectopic pregnancy rate ( number ectopic pregnancy ultrasound/number clinical pregnancy ) . Data Analysis : Descriptive analysis perform use SPSS software ( IBM Corp. , Version 22 ) . Associations categorical variable analyze use combination Chi-square Fisher 's Exact test . Associations continuous variable analyze use combination independent sample t-tests logistic regression . Sample Size Calculation : Based sample size calculation assumption ß = 80 % , α = 0.05 effect size 25 % clinical pregnancy rate , total 506 subject ( 253 per arm ) need recruit . This feasible within center two-year period less , base current number stimulate cycle per year 360 high rate compliance patient interest study .</detailed_description>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Indications IVF/ICSI include male factor , diminish ovarian reserve , tubal factor , ovulatory dysfunction unexplained infertility .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>luteal phase</keyword>
	<keyword>estradiol</keyword>
	<keyword>pregnancy rate</keyword>
</DOC>